tiprankstipranks
Blurbs

Evercore ISI Keeps a Buy Rating on Crispr Therapeutics AG (CRSP)

In a report released yesterday, Liisa Bayko from Evercore ISI maintained a Buy rating on Crispr Therapeutics AG (CRSPResearch Report), with a price target of $66.00. The company’s shares closed last Monday at $51.54, close to its 52-week low of $42.51.

According to TipRanks.com, Bayko is a 3-star analyst with an average return of 3.8% and a 38.9% success rate. Bayko covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Madrigal Pharmaceuticals, and Kiniksa Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Crispr Therapeutics AG with a $92.67 average price target, implying a 77.3% upside from current levels. In a report issued on May 11, Oppenheimer also maintained a Buy rating on the stock with a $150.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Crispr Therapeutics AG’s market cap is currently $4.05B and has a P/E ratio of 14.50.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.

Read More on CRSP:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles